WikiMD is the world's largest medical encyclopedia with
29,037 pages, 4,107,557 edits & 35,762,818 views.
Inotuzumab Ozogamicin
== Information about Inotuzumab Ozogamicin ==Inotuzumab ozogamicin is a humanized monoclonal antibody-cytotoxin conjugate which is used in the therapy of refractory or relapsed acute lymphoblastic leukemia.
Liver safety of Inotuzumab Ozogamicin
Inotuzumab ozogamicin has been linked to frequent serum enzyme elevations during therapy and with instances of clinically apparent acute liver injury, including acute sinusoidal obstruction syndrome which can be severe and even fatal.
Mechanism of action of Inotuzumab Ozogamicin
Inotuzumab (in" oh tooz' ue mab) ozogamicin (oh" zoe ga mye' sin) is a humanized monoclonal antibody to the human CD24 cell surface marker which is highly expressed on malignant lymphoblastic leukemia cells. The monoclonal antibody is conjugated to a cytotoxic agent from a class of calicheamicins called ozogamicin. When inotuzumab binds to CD24, it is inteRNAlized and the ozogamicin is released by the action of lysosomal enzymes on the linker molecule that joins it to the monoclonal antibody. The released intracellular ozogamicin causes breaks in double stranded DNA that leads to apoptotic cell death. This monoclonal antibody conjugate has been shown to be effective in inducing remissions in refractory acute lymphoblastic leukemia and was given accelerated approval for this indication in the United States in 2017.
Dosage and administration for Inotuzumab Ozogamicin
Inotuzumab ozogamicin is available as 0.9 mg of lyophilized powder in single dose vials under the brand name Besponsa. The recommended dose regimen varies by body weight, day of therapy and whether treating refractory vs relapsed acute lymphoblastic leukemia.
Side effects of Inotuzumab Ozogamicin
Common side effects include bone marrow suppression, infections, fatigue, fever, nausea, headache, abdominal pain and hemorrhage. Less common but potentially serious side effects include severe myelosuppression, severe infections, clinically significant bleeding and hemorrhage, infusion related reactions, QTc interval prolongation and embryo-fetal toxicity.
Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ
Cost and Coupons - Inotuzumab Ozogamicin
- Ozogamicin GoodRx compare cost & coupons for Inotuzumab Ozogamicin
- Find the lowest cost of Inotuzumab Ozogamicin
- Search for Coupons for Inotuzumab Ozogamicin
Reviews for Inotuzumab Ozogamicin
Learn more about Inotuzumab Ozogamicin
- Dailymed label info
- Scientific articles
- Drug portal Inotuzumab Ozogamicin
- toxicity info on Inotuzumab Ozogamicin
- FDA Inotuzumab Ozogamicin
Latest research (Pubmed)
External links
WikiMD needs you!
This WikiMD article Inotuzumab Ozogamicin is a stub.
If you are a healthcare professional familiar with the topic Inotuzumab Ozogamicin, or
A subject matter expert or authority on Inotuzumab Ozogamicin, you can help us.
About | Mission | Paid editors welcome!
| Inotuzumab Ozogamicin is part of WikiMD's Physician reviewed^ articles available 4free, 4all, 4ever! |
|---|
| Medicine: Health - Encyclopedia - Topics - Diseases - Cancer - Rare diseases - Random Page Navigation: Drugs - Wellness - Obesity - Diet - Ketogenic diet - W8MD weight loss diet - Editors: Recently Edited Pages - Alphabetical Order - Sponsors - USMLE The content on or accessible through WikiMD is for informational purposes only. WikiMD is not a substitute for professional medical advice. ^See full Disclaimers |
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP* |
